DAVID R SPRIGGS, MD
Osteopathic Medicine at York Ave, New York, NY
License number
New York 139819
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(646) 227-3275
Personal information
See more information about DAVID R SPRIGGS at radaris.comName
Address
Phone
515 E 72Nd St APT 17G, New York, NY 10021
304 Sandra Ln, Syracuse, NY 13212
1233 York St, New York, NY 10001
Organization information
See more information about DAVID R SPRIGGS at bizstanding.comMemorial Sloan Kettering CNCR - David R Spriggs MD
1275 York Ave, New York, NY 10065
Categories:
Oncology Physicians & Surgeons
Site:
Phone:
(212) 639-2203 (Phone)
Professional information
Dr. David Spriggs, New York NY - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
MEMORIAL DEVELOPMENTAL CHEMO GROUP
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
Certifications:
Internal Medicine, 1981, Medical Oncology, 2006
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
MEMORIAL DEVELOPMENTAL CHEMO GROUP
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
Education:
Medical School
University Of Wisconsin Medical School
Graduated: 1977
University Of Wisconsin Medical School
Graduated: 1977
David R Spriggs, New York NY
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Memorial Sloan-Kettering
1275 York Ave, New York, NY 10065
1275 York Ave, New York, NY 10065
Education:
University of Wisconsin at Madison (1977)
Method For Early Detection Of Ovarian Cancer
US Patent:
2007026, Nov 22, 2007
Filed:
Sep 10, 2004
Appl. No.:
10/595135
Inventors:
David Spriggs - New York NY, US
Jakob Dupont - Pelham NY, US
Jakob Dupont - Pelham NY, US
Assignee:
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY
International Classification:
G01N 33/574
US Classification:
435007100, 435007230
Abstract:
YKL-40 levels in serum and plasma samples provide as an indicator of both the presence of early stage ovarian cancer and of its aggressiveness. Thus testing for YKL-40 levels in patients at risk but not yet displaying symptoms associated with ovarian cancer, or in patients newly diagnosed with early stage ovarian cancer (Stage I or II) enhance both the detection of early stage ovarian cancer and selection of treatment protocols used for early stage ovarian cancer patients.
Antibodies To Muc16 And Methods Of Use Thereof
US Patent:
2013017, Jul 4, 2013
Filed:
Mar 25, 2011
Appl. No.:
13/635090
Inventors:
David Spriggs - New York NY, US
Dharmarao Thapi - Bayside Hills NY, US
Dharmarao Thapi - Bayside Hills NY, US
Assignee:
Memorial Sloan Kettering Cancer Center - New York NY
International Classification:
C07K 16/30
US Classification:
4241391, 5303879, 5303873, 435331, 536 2353, 436501, 435 723
Abstract:
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.